论文部分内容阅读
目的:探讨多药耐药基因-1(MDR-1)表达产物P-糖蛋白(P-gp)在鼻腔、鼻咽部恶性淋巴瘤组织中表达的临床意义。方法:用S-P免疫组化染色方法,检测37例鼻腔、鼻咽部恶性淋巴瘤组织中P-gp表达情况,并与患者的初诊与复诊、原发部位、病理类型、免疫组化分型等不同组织中P-gp的表达及预后相关性进行分析。结果:P-gp表达阳性的是复诊患者87.5%(7/ 8)、鼻咽部患者70.0%(7/10),与初诊患者34.5%(10/29)、鼻腔部患者37.0%(10/27)相比,均有明显差异;P-gp阳性表达患者耐药率88.2%(15/17),与P-gp阴性表达患者耐药率10.0%(2/20)相比,有明显差异。结论:P-gp阳性表达对预测耐药及临床医师选药、制定方案提供科学依据。
Objective: To investigate the clinical significance of expression of P-glycoprotein (P-gp) in nasopharyngeal and nasopharyngeal malignant lymphoma tissues with multidrug resistance gene-1 (MDR-1) expression. Methods: The expression of P-gp in 37 cases of nasal and nasopharyngeal malignant lymphoma was detected by SP immunohistochemical staining. The expression of P-gp in primary nasopharyngeal and nasopharyngeal malignant lymphoma was detected by SP immunohistochemistry. The expression of P-gp and prognosis in different tissues were analyzed. Results: The positive expression of P-gp was found in 87.5% (7/8) of the patients who returned to the clinic, 70.0% (7/10) of the nasopharyngeal patients, 34.5% (10/29) of the newly diagnosed patients and 37.0% 27). The drug resistance rate of P-gp positive patients was 88.2% (15/17), which was significantly lower than that of P-gp negative patients (10.0%, 2/20) . Conclusion: The positive expression of P-gp can provide a scientific basis for predicting the drug resistance and selecting the medicine for clinicians.